Fatigue is a frequent and distressing symptom in patients with multiple sclerosis (MS). In contrast, sleepiness, characterized by difficulties to stay awake and alert during the day, seems to be less prevalent in MS; however exact studies are lacking. In addition, there is a semantic confusion of the concepts of "fatigue" and "sleepiness", which are often used interchangeably. We conducted a systematic review of studies using the Epworth sleepiness scale (ESS) for the assessment of daytime sleepiness in patients with MS. The summarized results of 48 studies demonstrate that sleepiness, as indicated by elevated ESS scores, is less prevalent and less severe than fatigue but is present in a significant proportion of patients with MS. In most cross-sectional and longitudinal studies, there was a moderate association between ESS scores and various fatigue rating scales. Longitudinal studies on the effect of wakefulness-promoting agents failed to show a consistent improvement of sleepiness or fatigue as compared to placebo. It has also been shown that daytime sleepiness is frequently associated with comorbid sleep disorders that are often underrecognized and undertreated in MS. Sleepiness and potential sleep disorders may also precipitate and perpetuate fatigue in patients with MS and should be part of the differential diagnostic assessment. To support an appropriate decision-making process, we propose an algorithm for the evaluation of sleepiness as compared to fatigue in patients with MS.
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Sleepiness in multiple sclerosis 5 __________________________________________________________________________________ Fatigue is distinct from sleepiness, which is defined by the International Classification of Sleep Disorders (ICSD-3) as the inability to stay awake and alert during the day, leading to episodes of an irrepressible need for sleep or unintended lapses into drowsiness or sleep [18] ( Table 1) . Sleepiness predisposes people to develop serious performance impairments in daily functioning and is a risk factor for potentially life-threatening domestic, occupational, and vehicular accidents [18] . The complaint of excessive sleepiness during the normal wake period is also a pivotal symptom for sleep disorders of hypersomnolence, as classified by the ICSD-3.
---Insert Table 1 about here ---
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Sleepiness in multiple sclerosis 6 __________________________________________________________________________________ A widely used approach to evaluate daytime sleepiness on a subjective level, is the employment of the Epworth sleepiness scale (ESS), a self-administered 8-item questionnaire assessing sleep propensity [23] . A total ESS score greater than 10 (range 0 to 24) is indicative for increased sleepiness. In the instructions, the ESS asks for the likelihood of dozing off or falling asleep in different everyday situations, "in contrast to feeling just tired" [23] . Thus, the ESS quantifies daytime sleepiness using behavioral correlates and circumvents subjective evaluations of states of tiredness, sleepiness or fatigue. Assessing sleepiness by this approach avoids semantic confusion, which is a problem when using fatigue questionnaires that are based on self-reports.
The aim of this systematic review is to summarize the results of published studies using the ESS for the assessment of daytime sleepiness in patients with MS. We focused on the frequency and extent of daytime sleepiness compared to fatigue as assessed by selfadministered rating scales such as the FSS or other related scales (e.g. neurological fatigue index, NFI-MS, modified fatigue impact scale, MFIS).
Sleepiness in multiple sclerosis 7 __________________________________________________________________________________
Methods
Literature search and identification of studies
Studies were identified by searching electronic databases and scanning reference lists of articles. The present review only includes studies that used the ESS, which was published in 1991, as an assessment-tool. Therefore, articles that were published before 1991 were not considered. No other limits (e.g. language restrictions) were applied. The search strategy was developed by a subject specialist (RP) in collaboration with an information specialist and librarian who is trained and experienced in conducting comprehensive literature searches (HK). Database searches were conducted by HK on May 14, 2014, with an update on April 22, 2015. In addition, registers for clinical trials were searched on August 04, 2015. While our search strategy was not peer-reviewed, we strived to design, carry out and report the literature search according to current checklists and recommendations [24, 25] .
The research question was translated into two search concepts, "multiple sclerosis" and "Epworth sleepiness scale" that were combined using the Boolean operator AND. The search strategy was adapted to the various databases and search interfaces. This included selecting feasible search terms, syntax, and relevant subject headings. The searches were designed to be M A N U S C R I P T
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Sleepiness in multiple sclerosis 8 __________________________________________________________________________________ A detailed documentation of the searches allowing for replication, can be seen in Appendix 1, which is available as an electronic supplement. The reference lists of articles that were regarded eligible were scanned by AF, NK, and RP.
Eligibility assessment
Eligibility assessment was performed independently in a standardized manner by three reviewers (RP, AF, and NK). Disagreements were solved by consensus. If no agreement could be reached, another author (TCW) was designated to make the final decision. Studies were included only if the contained the following: (a) original investigations -articles in which no original data was published were excluded (e.g. mostly reviews, letters to the editor etc.). (b) published ESS data -the article had to provide statistical data of the ESS score (e.g. mean, median). (c) adult (≥ 18 years) patients with MS. (d) sufficient sample sizes, (n ≥ 10) that allowed for inferential statistics, i.e. no case reports or studies providing only descriptive data.
Finally, no restrictions concerning duration of illness, subtype of MS or other specifications were applied. We also did not limit this review to studies with special interventions.
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Results
Study selection
Disagreements regarding eligibility assessment between the reviewers (AF, RP, and NK) were minor and could be resolved by consensus. Our cross-database search yielded 607 records.
After removing duplicates, 521 records remained and were screened for relevance. 440 records were excluded because no original data was published, disorders other than MS were investigated (e.g. sleep disorders, Parkinson`s disease), or there was no ESS data specified in the abstract and no full text articles were available. If the record was categorized as potentially relevant, the full text article was assessed for eligibility. 21 studies were not included because the ESS was not used as an assessment tool. In three studies, the number of participants was too small (< 10) to be included. One of the full text articles was excluded because the patients were younger than 18 years of age. Ten of the full text articles were excluded because no sufficient statistical ESS data was published. However, if the corresponding author of these studies could provide ESS data on request, the articles were included in the study selection (n = 5; see supplementary material -Appendix 2). Finally, our systematic review comprised 48 studies (Table 2) [26-73].
---Insert Table 2 about here ---
The flow diagram of the selection process is presented in Figure 1 . Detailed information of articles excluded by full-text review is given in Appendix 4 of the supplementary material.
M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT
Sleepiness in multiple sclerosis 10 __________________________________________________________________________________
Review findings
No systematic epidemiological studies on the prevalence of daytime sleepiness in MS patients using the ESS as a main outcome parameter have been published so far. Out of 48 original articles, about one-third (30%) of the studies comprised a larger MS sample size, i.e. at least 100 patients were included. The majority of articles (67%) had a cross-sectional study design, while the others, in most cases, used a long-term longitudinal study design to assess different treatment effects of medication and other interventions such as treatment of sleep disorders [58] [59] [60] [61] [62] [63] [64] [65] [66] [67] [68] [69] [70] [71] [72] . In particular, two studies investigated the effect of continuous positive airway pressure (CPAP) treatment on respiratory disturbances occurring during sleep, which are defined as sleep-related breathing disorder (SRBD) [61, 64] . As the ESS and FSS are traitspecific questionnaires, potential improvements of both scores depend on lasting interventions (i.e., from one week to several months). Thus, we did not consider temporary pharmacological effects lasting only a few hours as longitudinal data [51] . We also used baseline results of longitudinal studies to gain cross-sectional data on ESS-and fatigue scores.
Out of all investigations, 19 studies provided data on the correlation between the ESS and the FSS (89%) or other fatigue scales (e.g. NFI-MS, MFIS). Finally, for objective measures of sleep disorders in MS patients, nine studies using polysomnography (PSG) [27, 30, 33, 36, 40, 41, 49, 56, 61] and two study applying actigraphy [26, 65] were used.
Cross-sectional data
Among the studies reporting on fatigue levels (n = 40), increased fatigue scores (e.g. FSS > 4 or MFIS > 34) were found in the vast majority (78%) and were mostly well above their critical cut-offs. Increased daytime sleepiness, as defined by a mean ESS score above 10, was detected in 11 studies (23%) reporting ESS values in either total samples or subgroups of patients. The largest non-systematic survey of sleep disorders in the MS population to date, M A N U S C R I P T
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Sleepiness in multiple sclerosis 11 __________________________________________________________________________________ comprising 2,375 patients, suggests increased daytime sleepiness in 30% of the respondents based on an ESS score above 10 [31] (see Table 2 ). Within the patient groups, elevated mean ESS scores mostly ranged from 10.5 to 12.5 and were close to their critical cut-off value.
Only a single study, with 21 fatigued MS patients, showed a higher mean ESS score for the whole group (15.7) [33] . On an individual level, the proportion of MS patients with elevated ESS scores was up to 61% in those studies that provided frequency data (23 studies in total).
Six studies with population sizes of at least 100 MS-patients reported frequencies of increased ESS scores between 19% and 53%. 
Longitudinal data
Our search yielded 16 studies reporting ESS data at baseline and at follow-up (see Table 3 ).
Six studies specifically evaluated the efficacy of wakefulness-promoting agents (e.g. modafinil or armodafinil) on fatigue or sleepiness. In two placebo-controlled studies, modafinil [66] or armodafinil [60] did not significantly improve fatigue or sleepiness at all.
Among two further studies using placebo, one demonstrated a substantial placebo effect on fatigue with no additional benefit from modafinil [68] , whereas the other study only reported M A N U S C R I P T Table 3 about here----
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Discussion
In our comprehensive literature search we strived to find all available evidence on the use of the ESS as an assessment tool in adult patients with MS. Finally, we identified 48 studies that fulfilled our inclusion criteria.
The majority of studies showed clinically significant fatigue in MS, whereas sleepiness was reported to be less frequent and less severe. Nevertheless, a substantial number of fatigued patients showed increased ESS scores as well. Some studies investigating the association between sleepiness and fatigue revealed weak to moderate correlations between both conditions, mainly depending on the presence of comorbid sleep disorders. In general, sleep disorders such as SRBD [61, 74] 
The extent of sleepiness and fatigue in MS
In almost all (85%) selected studies using the ESS as an assessment tool, fatigue scores as indicated by elevated fatigue rating scores, was present in the majority (78%) of the reviewed studies that provided fatigue data. This finding is in accordance with previous epidemiological studies that showed high prevalence of fatigue in patients with MS [7] [8] [9] [10] .
In contrast, increased daytime sleepiness (mean ESS score > 10) was observed less frequently (26% of the studies), comprising a limited number of patients with MS (see Table 2 ). Two studies reporting mean ESS scores of 15.0 and 15.7 referred to two subgroups that were a priori defined as sleepy or fatigued comprising only 6 (total n = 12) or 11 (total n = 21) MS patients, respectively. [27, 33] . Of note, the study by Beran and colleagues [27] used the ESS as a specific selection criterion (ESS score ≥ 9) for patients with and without daytime sleepiness. In few other studies indicating pathological sleepiness on a group level, patients were selected regarding fatigue (fatigue descriptive scale ≥ 5) in combination with complaints of sleep disturbances [58] . This was particularly the case for interventional studies investigating the efficacy of wake-promoting substances [66, 68] . In some other studies showing increased ESS scores in patient subgroups, the patients had specifically been selected for increased fatigue levels [26, 33, 39, 56] .
In all studies with more than 150 MS patients, the mean ESS score did not indicate increased sleepiness. In the two largest samples of MS patients by Mills and Young [47] (n = 559 with valid ESS data) and Brass and colleagues [31] (n = 2,375), the average ESS scores were 7.9 (mean) and 8 (median), respectively -well below the critical cut-off score. Despite the low mean ESS scores of the study sample published by Brass and colleagues [31] , 30% of the patients scored above 10, indicating increased sleepiness. In general, daytime sleepiness does not seem to be a prominent and frequent symptom in MS patients on a group level, but may be present in a substantial number of patients (ranging up to 61%) on an individual level ( 
Semantic confusion of concepts
Sleepiness and fatigue are two interrelated but distinct phenomena [19] , that can be easily as an increased propensity to fall asleep during the day assessed by the ESS [79] . In insomnia research, it is well established to differentiate between both concepts as clinical criteria, as patients with primary insomnia complain about excessive fatigue during the day, but not about sleepiness as defined above [80] . Because the meaning of both terms differs between languages, the assessment of fatigue and sleepiness is even more difficult. This is especially true for the FSS, which uses the term "fatigue" without any further specifications.
There is converging evidence that fatigue and sleepiness are two different concepts with a limited overlap of symptoms. Because fatigue is mostly poorly defined, applied assessment tools are often not precise enough to distinguish between both conditions [81] . Few original studies on MS (e.g. [27, 46] ) have explicitly distinguished between the concepts of sleepiness and fatigue and have explored the relationship between both clinical conditions in more detail.
In many other studies, the terms fatigue and sleepiness are used inconsistently, sometimes even synonymously [76] . In general, the terms fatigue, tiredness and sleepiness are rarely explored differentially, and their lack of distinction is a major issue in clinical research and practice [21] .
The impact of sleep disorders
Fatigue in MS appears to be multifactorial, with a component of fatigue directly attributable to the MS disease process (primary fatigue), as well as to secondary chronic illness factors, such as pain, medication, depression or other comorbidities, including poor sleep [4, 82, 83] .
It has been reported that at least 50 % of patients with MS complain about sleep disturbances or poor sleep [5, 84] The largest study included in our review comprised 2,375 MS patients and focused on the frequency of sleep disorders and their association with fatigue and sleepiness [31] . As assessed by the ESS, the prevalence of daytime sleepiness was reported to be 30%, while that for abnormal fatigue measures was 60%. Increased sleepiness and fatigue scores were associated with positive screenings for insomnia, SRBD, and RLS that showed prevalence rates of 32%, 38%, and 37%, respectively. Thus, more than 70% of this large MS cohort screened positive for at least one or more sleep disorders [31] . Studies using sleep questionnaires, actigraphy or PSG found a positive correlation between subjectively or objectively measured disrupted sleep and fatigue in MS patients [26, 27, 40, 48, 56, 61] .
Kaynak and colleagues [41] found that the total arousal index was higher in a subgroup of fatigued patients compared to a non-fatigued group. However, another polysomnographic study investigating sleep-related correlates of fatigue in MS, reported conflicting results [36] .
In the case of increased daytime sleepiness, sleep disorders associated with hypersomnolence may be highly prevalent, yet underrecognized, clinical conditions in MS contributing to increased fatigue [29] .
Methodological constraints
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Sleepiness in multiple sclerosis 18 __________________________________________________________________________________ Our systematic review provides a qualitative and descriptive survey of the summarized studies that include original data. We may have failed to identify all relevant studies as the ESS might not be mentioned in the fields available via the databases' search interfaces. There was noticeable heterogeneity between studies with respect to study design, experimental procedures, and the quality of data sets on ESS or FSS. Therefore, no meta-analysis of effect sizes regarding sleepiness or fatigue scores was feasible for this review. As an operational definition of daytime sleepiness, we used sleep propensity as assessed by the ESS. However, the ESS is a subjective rating of sleep propensity in daily life and covers only one specific aspect of the multi-dimensional concept of sleepiness [88] . In addition, even though the ESS is widely used as an assessment tool in clinical practice and research, this instrument has only modest psychometric properties. The reliability and validity of the ESS as a unidimensional scale for sleepiness has been questioned by a number of studies [89] . However, due to the huge body of findings on the ESS and the knowledge of its strengths and limitations, utilizing the ESS as an assessment tool for evaluating sleepiness in MS seems to be an appropriate approach. Studies on MS comparing subjective and objective measures of sleepiness (e.g. multiple sleep latency test, maintenance of wakefulness test, or pupillography sleepiness test) are rare [27, 40, 41, 49, 90] and beyond the scope of our review but warrant further research.
Implications for clinical practice
Sleepiness may confound measures developed to assess fatigue (see also Table 1 Although sleepiness seems to be less prevalent and less severe than fatigue, it is present in a substantial number of patients with MS. Yet, sleepiness and tiredness-related fatigue due to sleep disturbances are both underrecognized and undertreated clinical conditions in MS that are in need of specific diagnoses and appropriate treatments.
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Practice points
• Sleepiness and fatigue are two interrelated, albeit distinct concepts with limited overlap.
• In patients with MS, fatigue is more prevalent and severe than daytime sleepiness.
• Fatigue without sleepiness is frequent in MS, whereas sleepiness without fatigue is rare.
• High scores on fatigue scales are often accompanied by increased daytime sleepiness. Therefore, the ESS should also be applied in MS patients with increased fatigue scores. Both clinical conditions may be associated with sleep disorders.
• Increased sleepiness, as well as significant complaints of fatigue and poor sleep, warrants further assessment of potential comorbid sleep disorders or negative effects of hypnotic use. Elevated ESS scores may be indicative of sleep disorders associated with hypersomnolence and demand specific treatment of daytime sleepiness.
• The clinical significance of daytime sleepiness in MS patients remains unknown; nevertheless it may be presumed that it diminishes the quality of life of the patients.
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Research agenda
• The assessment of the prevalence of daytime sleepiness in MS is needed. This requires a systematic epidemiological study using the ESS or other questionnaires in a large population of patients with MS focusing on the assessment of daytime sleepiness as the inability to stay awake and alert.
• Cross-sectional studies on distinct subtypes of MS should take into account both concepts of fatigue and sleepiness, using adequate and established assessment tools for each condition.
• Longitudinal studies are necessary to clarify whether the course of MS is related to the development of fatigue, sleepiness or sleep disorders.
• Prospective studies following MS patients with different subtypes should be performed to allow for the analysis of the association between fatigue, sleepiness or potential sleep disorders and the clinical MS status of the patients including the severity of disability as well as MRI findings.
• Studies comparing objective assessments of daytime sleepiness (e.g. maintenance of wakefulness test, pupillography, vigilance or sustained attention tasks) with subjective measures of sleepiness and fatigue are needed in patients with MS
• In MS, systematic studies using the ESS or other screening tools for hypersomnolence are needed. Abnormal findings should be validated using more specific assessments (e.g. polysomnography). 
Symptoms
• Feelings of tiredness, exhaustion, weariness or lassitude
• not necessarily associated with sleep pressure
• no definite sleep drive when resting (e.g. lying down to relax)
• Decreased level of alertness or wakefulness
• increased tendency to fall asleep or doze off unintentionally
• sleep drive when resting (e.g. lying down to nap)
Semantics
• Tiredness is commonly used as synonym (e.g. by insomniacs)
• Tiredness is commonly used as synonym (e.g. by narcoleptics)
Characteristics in MS
• Common and most troublesome symptom
• strong negative impact on social and occupational functioning Table 2 Summarized studies using the Epworth sleepiness scale (ESS) as an assessment tool in patients with multiple sclerosis (MS) -cross-sectional studies 
